References
1. Directive 1999/45/EC of the European Parliament
and of the Council of 31 May 1999 concerning the
approximation of the laws, regulations and
administrative provisions of the Member States
relating to the classification, packaging and labelling
of dangerous preparations.
2. Schade DS, Eaton RP. Metabolic and clinical
significance of ketosis.
Special Topics in
Endocrinology and Metabolism
1982; 4:1–27.
3. Wiggam MI, O’Kane MJ, Harper R, Atkinson AB,
Hadden DR, Trimble ER, Bell PM. Treatment of
diabetic ketoacidosis using normalization of blood
3-hydroxybutyrate concentration as the endpoint of
emergency management.
Diabetes Care 1997;
20:1347–52.
4. Harano Y, Kosugi K, Hyosu T, Suzuki M, Hidaka H,
Kashiwagi A, Uno S, Shigeta Y. Ketone bodies as
markers for Type 1 (insulin-dependent) diabetes and
their value in the monitoring of diabetes control.
Diabetologia 1984; 26:343–8.
5. Ubukata E. Diurnal variation of blood ketone
bodies in insulin-dependent diabetes mellitus and
non-insulin-dependent diabetes mellitus patients: The
relationship to serum C-peptide immunoreactivity
and free insulin.
Ann Nutr Metab 1990; 34:333–42.
6. Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo
RA. Metabolic effects of low-dose insulin therapy on
glucose metabolism in diabetic ketoacidosis.
Diabetes
1988; 37:1470–77.
7. Hale PJ, Crase J, Nattrass M. Metabolic effects of
bicarbonate in the treatment of diabetic ketoacidosis.
Br Med J 1984; 289; 1035–8.
References
89
To Previous Page
Loading...
Need help?
General